INDSWFTLTD2023-04-012023-06-30 INDSWFTLTD2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member INDSWFTLTD2023-06-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524652 INDSWFTLTD NOTLISTED Ind-Swift Limited Equity 2023-04-01 2024-03-31 2023-08-10 2023-07-31 INR Lakhs First quarter 16:30:00 18:30:00 2023-08-10 2023-08-10 Not applicable Single segment Pharmaceuticals 2023-04-01 2023-06-30 Unaudited Standalone 1485360000.00 56304000.00 1541664000.00 488104000.00 137127000.00 281529000.00 183481000.00 149451000.00 67210000.00 211138000.00 1518040000.00 23624000.00 0.00 23624000.00 0.00 0.00 0.00 0.00 23624000.00 0.00 0.00 0.00 0.00 23624000.00 0.00 23624000.00 0.00 0.00 108329000.00 2 0.44 0.44 0.00 0.00 0.44 0.44 Notes:- 1 The above financial results have been prepared in accordance with IND-AS prescribed under section 133 of Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulation 2015. 2 Deffered Tax Asset/Liability will be accounted for at the year end. 3 Exceptional/Extraordinary items for the qtr ended 31st March, 2023 includes waiver of principle and Interest on Loan for Rs.6057.87 lacs. 4 The Company is exclusively in Pharmaceutical business. 5 Previous period/ year figures have been re-grouped/Re-arranged where ever necessary. 6 The above audited Standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on10th, Aug.,2023. Other Expenses 211138000.00 0.00 0.00